TABLE 1.
Summary of individuals sampled, ocular clinical signs (KC), and results of specific qPCR and IgG antibodies against M. conjunctivae
| Yr of sampling | Mo of sampling | No. of KC positives/no. sampleda | qPCR |
ELISA |
No. of positive ibexes per technique/no. of total positive ibexes |
||||
|---|---|---|---|---|---|---|---|---|---|
| No. of positives/no. sampled | Prevalence (% [95% CI]) | No. of positives/no. sampled | Prevalence (% [95% CI]) | qPCR+/KCa | ELISA+/KCa | ELISA+/qPCR+ | |||
| Captive ibexes | |||||||||
| 2010 | November | 0/64 | 0/64 | 0 (0–5.7) | 0/0 | ||||
| 2011 | November | 0/51 | 0/51 | 0 (0–7.0) | 0/0 | ||||
| 2013 | July | 2/2 | 2/2 | 1/2 | 2/2 | 1/2 | 1/2 | ||
| August | 12/48 | 17/48 | 35.4 (23.4–49.6) | 33/48 | 68.7 (54.7–80.0) | 6/12 | 10/12 | 14/17 | |
| September | 12/46 | 4/46 | 8.7 (3.4–20.3) | 25/46 | 54.3 (40.2–67.8) | 4/12 | 5/12 | 1/4 | |
| November | 8/46 | 2/46 | 4.3 (1.2–14.5) | 20/43 | 46.5 (32.5–61.1) | 1/8 | 2/8 | 1/2 | |
| 2014 | November | 1/69 | 52/69 | 75.3 (64.0–84.0) | 10/26 | 38.5 (23.4–59.3) | 1/1 | 0/1 | 13/21 |
| Free-ranging ibexes | |||||||||
| 2013–2014 | October–April | 0/14 | 1/17 | 5.9 (0.3–27.0) | 1/13 | 7.8 (0.4–33.3) | 1/17 | 0/1 | |
a
Ocular clinical signs of current inflammation (IKC stages from I to III) and healing (IKC stage V) or past infections (IKC stages VI).